Colistin Dosage without Loading Dose Is Efficacious when Treating Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia Caused by Strains with High Susceptibility to Colistin

PLoS One. 2016 Dec 19;11(12):e0168468. doi: 10.1371/journal.pone.0168468. eCollection 2016.

Abstract

Objectives: This study aims to analyze the mortality and the length of ICU stay (LOS) of A. baumannii VAP compared to respiratory colonization in patients with mechanical ventilation (MV).

Methods: A prospective cohort study was performed in an ICU of adult patients (February 2010-June 2011). One hundred patients on MV with A. baumannii in lower respiratory airways were recruited, and classified as VAP or airways colonization according to CPIS criteria, with a punctuation ≥6. LOS, 30-days mortality, A. baumannii bacteremia, and clinical features including antibiotic therapy were recorded. Multivariate analysis (linear and Cox regression) and survival analysis (Kaplan-Meier curves) were performed.

Results: Fifty-seven VAP and 43 colonized A. baumannii patients were analyzed. Among the A. baumannii strains, 99% were non-susceptible to carbapenems and the MIC90 of colistin was 0.12 mg/l. Therapy was appropriate in 94.6% of VAP patients, most of them with colistin 6 MIU/day, although in 13 (23.6%) cases colistin was started 48 hours after the onset of VAP. Mortality was similar in both groups (VAP 24.6% vs. colonized 27.9%, p = 0.7). Bacteremia and acute kidney insufficiency were associated with decreased survival (p = 0.02 and p = 0.04, respectively) in VAP patients. LOS was 21.5 (11.5-42.75) vs. 9 (6-22) days for VAP and colonized patients (p = 0.004). VAP (p = 0.003) and age (p = 0.01) were independently related to a longer LOS.

Conclusions: Multidrug-resistant A. baumannii VAP treated with colistin does not have a different mortality compared to lower airways colonization, among patients on mechanical-ventilation, in a setting of high susceptibility to colistin of A. baumannii.

Publication types

  • Clinical Trial
  • Observational Study

MeSH terms

  • Acinetobacter baumannii / metabolism*
  • Adult
  • Bacteremia* / drug therapy
  • Bacteremia* / microbiology
  • Bacteremia* / mortality
  • Carbapenems*
  • Colistin / administration & dosage*
  • Disease-Free Survival
  • Drug Resistance, Multiple, Bacterial / drug effects*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Pneumonia, Ventilator-Associated / drug therapy
  • Pneumonia, Ventilator-Associated / microbiology
  • Pneumonia, Ventilator-Associated / mortality
  • Prospective Studies
  • Survival Rate

Substances

  • Carbapenems
  • Colistin

Grants and funding

The present study has been granted by the Instituto de SaludCarlos III (PS09/01427) and supported by Plan Nacional de I+D+i and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0001) - co-financed by European Development Regional Fund "A way to achieve Europe" ERDF. RAM has a Rio Hortega grant from the Instituto de Salud Carlos III (CM14/00179). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.